Fig 2.
Survival from time of relapse of patients with unsuspected relapse detected by monitoring that included iodine-123–metaiodobenzylguanidine (123I-MIBG) scans (blue line), unsuspected relapse detected by monitoring that included iodine-131–metaiodobenzylguanidine (131I-MIBG) scans (gray line), and symptomatic relapse (gold line; P < .001).